Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.

相似書籍

• Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
  由: Davies, Jane C., et al.
  出版: (2016)
• An Open-label Extension Study of Ivacaftor in Children With CF and a CFTR Gating Mutation Initiating Treatment at Age 2-5 Years (KLIMB)
  由: Rosenfeld, Margaret, et al.
  出版: (2019)
• Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial
  由: Davies, Jane C., et al.
  出版: (2021)
• Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
  由: Wainwright, C.E., et al.
  出版: (2015)
• CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on Ivacaftor
  由: Kramer, Elizabeth L., et al.
  出版: (2016)